Category Archives: Stem Cell Doctors

South Carolina toddler survives rare cancer and the risky procedure used to treat it – USA TODAY

Hailie Hyman holds her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

GREENVILLE, S.C.Hailie and Treylin Hyman saw the bruising on their baby girls leg as a sign that the active 1-year-old was learning to walk.

But as a blood test would later reveal, little Maci was actually suffering from an extremely rare blood cancer that threatened her life without a risky treatment - atreatmentalmost as dangerous as the disease.

In the beginning, it was very scary, Hailie Hyman told The Greenville News.

I couldnt think of anything but the bad things, she confessed. It was all about the statistics. And the statistics arent good.

Terrifying months followed the diagnosis, punctuated by one critical complication after another, leaving the Boiling Springs couple to wonder if Maci would survive.

Somehow, though, the blue-eyed toddler pulled through.And now her family is looking forward to a special Thanksgiving with much to be grateful for.

Alyssa Carson is 18 and has a pilot's license: She wants to be in the crew that colonizes Mars

The Hymans journey began last February atMacis 1-year-old well-child checkup.

We had no idea anything was wrong, her mom said.But they did a routine (blood test) and a couple of hours later, we got a call saying her platelets were very low.

The Hymans were referred to a hematologist who found other abnormalities in Macis blood and scheduled a bone marrow biopsy to investigate further.

Hailie Hyman holds her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

During the procedure, the child suffered an aneurysm in an artery and went into cardiac arrest. The team performed CPR on her for 20 minutes before she was stabilized, her mom said.

Later, in the pediatric intensive care unit, she suffered internal bleeding, too.

It was really hard, she said. There were many nights that I would just pray and pray and pray.

Initially believing Maci had leukemia, doctors subsequently determined she had myelodysplastic syndrome, or MDS.

The condition occurs when abnormal cells in the bone marrow leave the patient unable to make enough blood, according to the American Cancer Society.

Its rare, afflicting as few 10,000 Americans a year, though the actual number is unknown.

Maci Hyman, 1, interacts with hospital staff before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

In children, its rarer still. Most people arediagnosed in their 70s.

We were told that just four out of 1 million children get it every year, Hailie Hyman said.

That made the diagnosis elusive at first, said Dr. Nichole Bryant, a pediatric hematologist-oncologist with Prisma Health-Upstate, formerly Greenville Health System.

Shes the only one Ive seen in my career, she said.

Maci had to have regular blood transfusions, antibiotics and other medications to fight the MDS, Bryant said. But the only hope for a cure was a stem cell transplant at the Medical University of South Carolina in Charleston.

When they said that was the only treatment plan for MDS, I of course went to Google, Hailie Hyman said. I read about transplant patients and ...all the complications. It was terrifying. But no matter how many bad things I saw, we had to do it. There is no other option.

The transplantis extremely risky.

Hailie Hyman looks at a fish tank with her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

First, high doses of chemotherapy are given to destroy the diseased bone marrow, leaving the patient without an immune system, so fighting infections becomes a challenge. Then healthy donor marrow is infused.

Its also fraught with potentially life-threatening complications, including graft vs. host disease, which occurs when immune cells from the donor attack the patients body, Bryant said. Other complications include permanent kidney damage and gastrointestinal problems.

They have to go to hell and back, she said. But its the only option for long-term survival.

Maci had a really rough start, suffering lots and lots and lots of complications, Bryant said.

Her kidneys failed, so she wound up on dialysis. When she couldnt breathe on her own, she was put on a ventilator. And because she couldnt eat, she had to be tube fed.

Hailie Hyman looks at a fish tank with her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

She had blistering sores in her mouth and throughout her GI tract, her mom said. Because her liver wasnt functioning properly, her abdomen filled up with fluid that had to be drained. She was bleeding so profusely in her lungs that one of them collapsed.

Maci, who was sedated through much of it, was put on full life support, she said.

That night we almost lost her, her mom said. We were in the hallway crying our eyes out. We didnt know what do to or think. It was pretty scary for a while.

Somehow, Maci made it.

There were so many times during her first months that it seemed like she would not survive, Bryant said. So the fact that she is here ... is really a miracle.

Macis family found an unrelated donor through the National Marrow Donor Program, enlisting hundreds of other people to join the registry in the process, Bryant said.

Nichole Bryant, M.D.(Photo: Provided)

It was an important part of their journey that maybe didnt directly benefit Maci, she said. But if everybody did that, we wouldnt have difficulty finding a donor for anybody.

Doctors have no explanation for why Maci got MDS. She didnt carry the genetic mutation for it and there is no family history.

She is a rare child - and not in a good way, her mom said, adding,Youve got to laugh sometimes or youre going to cry.

A dying man wanted one last beer with his sons: The moment resonated with thousands

Maci was admitted to MUSC on June 2 and released on Oct. 14.

The Hymans, both 22, spent the entire time in Charlestonwhile Hailies mom cared for their older daughter, Athena, now 2.

Treylins employer held his welding job open for him. And other friends and family members did what they could to help.

We had many, many people very generously donate to us to cover expenses at home and living expenses where we were, Hailie Hyman said.

We are thankful for everyone who helped us through it the cards, the gifts, the donations. Every single cent is greatly appreciated.

Maci's doing well, but recovery from a transplant can take months to years, Bryant said.

Her kidneys are functioning again so she was able to come off dialysis. But she still must take many medications, including anti-rejection drugs that suppress her immune system and leaveher at risk for infection. And she still must be tube fed.

She is miles ahead of where she was two months ago, Bryant said. But she still has a long way to go. Its a long, long road.

Macis mom says she can be up and playing one day and flopped over on the couch another. She still experiences a lot of nausea and vomiting, but is doing well compared to where she was.

Hailie Hyman pulls her daughter Maci, 1, in a wagon in the hallway before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

So as the nation pauses to give thanks this Thanksgiving, she says the family will be countingtheir many blessings family andfriends, Gods mercy, andthe doctors and nurses who saved Macis life.

She has battled a lot and overcome a lot, she said. I have no doubt she will be able to get through.

Want to know more about becoming a marrow donor? Go to bethematch.org.

Follow Liv Osby on Twitter:@livgnews

104-year-old woman bags first buck: 'Never underestimate the power of our senior citizens'

Indiana hospital sued: More than 1,000 patients potentially exposed to HIV or hepatitis

Read or Share this story: https://www.usatoday.com/story/news/health/2019/11/28/south-carolina-toddler-survives-rare-blood-cancer-risky-procedure/4321002002/

Read more here:
South Carolina toddler survives rare cancer and the risky procedure used to treat it - USA TODAY

Mum shares heart-wrenching photos to show the ‘reality of childhood cancer’ – Mirror Online

The family of a little girl who was diagnosed with cancer at just 14 months old have released a photo of her undergoing treatment to show the devastating effects of childhood cancer.

Sophia Soto was found to have Stage 4 Neuroblastoma shortly after her first birthday when tumours were discovered behind her eyes and on her kidney.

It began a relentless six month period of treatment, during which brave Sophia endured 60 rounds of chemotherapy, 20 rounds of radiation and a stem cell transplant.

Sophia battled through and has now been in remission for five years, unrecognisable from the girl who appears in the heartbreaking images from March 2014.

Her mum, Rosie, says no one could imagine what her six-year-old daughter, and herself as a parent, have been through looking at her now.

"The picture of Sophia upset really does home in on the reality of childhood cancer," she said.

"She was having a lead put on her chest for her treatment - which she didn't want - hence why Sophia was so upset.

"I look back at the picture now and wonder how I did it; it was so hard watching my little girl so ill."

Rosie, from Florida, became concerned about her young daughter after noticing she was developing bruising around her eyes, which she claims doctors dismissed as a result of a bump or fall.

The mum followed her instincts and continued to search for an answer, taking Sophia to an eye specialist who 'knew straight away' the bruising was being caused by tumours.

Rosie continued: "Sophia kept getting bruising on her eyes and I didn't recall her falling over or anything, so I didn't understand where they were coming from.

"I kept taking her to the doctors because the bruising wasn't going away, but they just said it must have been from a bump or something.

"Sophia wasn't referred for a scan or biopsy until I went to see an eye specialist.

"She was sent for an MRI where black spots appeared on the scans confirming the tumours behind her eyes.

"It was then the biopsy which found the tumours on one of her kidneys as well which led to her stage 4 Neuroblastoma diagnosis."

Following half a year of gruelling treatment, Sophia has been in remission since November 2014 and has now been medication free for two years.

The youngster, who loves to dance and has dreams of becoming a vet, isn't yet classified as 'cancer free' and still requires check ups every six months.

The tumours remain behind Sophia's eyes, which cannot be removed due to their placement, but doctors believe they are benign and not causing harm.

"Doctors are reluctant to remove the tumours Sophia currently has behind her eyes as they've said it would be likely the surgery to disfigure her face," said Rosie.

"Whilst they are tumours, doctors are reasonably confident that they are not cancerous so we have decided to not have the surgery right now, but it may be something she has when she's older.

"No one can imagine what she went through looking at her now - she just looks like a normal regular child.

"Sophia has her moments when she asks about when she was sick and has questions about her treatment scars, but overall she's a pretty happy girl.

"If I was to say anything to other parents with children battling cancer, I'd say to them to not give up, stay positive and keep your faith.

"It's really important not to compare your child's process to anyone else as everyone battles illnesses differently as every situation is different.

"We're over the moon that Sophia is now doing so well - we're really blessed that she's such a fighter."

See the rest here:
Mum shares heart-wrenching photos to show the 'reality of childhood cancer' - Mirror Online

Diabetic foot wounds kill millions, but high-tech solutions and teamwork are making a difference – The Conversation US

What if someone told you that theres a disease you could catch where you couldnt feel any symptoms coming on? And that this occurs every 1.2 seconds somewhere in the world?

What if you were stricken with this disease then there would be a 5% chance youd lose a limb within a year and a 50-70% chance youd be dead in five years? What if you were told that this problem cost more than the five most expensive cancers in the U.S. but far less than one one-thousandth of comparative federal and private funding is spent on attacking it?

Ladies and gentlemen, please allow me to introduce you to the humble diabetic foot ulcer. While the problem may strike at the end of the body, far away from the heart or the brain, its effects are far-reaching.

I have spent my career treating and researching the lower extremity complications of diabetes. Based on my research and experience, I believe our society could eliminate immeasurable suffering if we collectively paid more attention to this problem.

OK, I know this isnt a sexy topic. Foot wounds are ugly. Many people who have them are poor. But bear with me. They are a reality for far too many Americans and people across the globe. The ages of these patients are bimodal, in that there is one population of people who are old and getting older. Conversely, with more and more people being diagnosed with Type 2 diabetes earlier, there is a population that is younger than ever being afflicted with wounds, infections and amputation. Ignoring the problem is an example of ignoring the needs of a silent and vulnerable population.

About 31 million people in the U.S. have diabetes, and about half a billion worldwide.

Diabetic foot ulcers develop because people with diabetes slowly lose the gift of pain. Over many years, people with diabetes lose feeling in their extremities. This occurs first and generally most profoundly in their feet.

Once this occurs, people with diabetes might wear a hole in their foot, just as you or I might wear a hole in a sock or shoe. This hole is called a diabetic foot ulcer.

About half the time, the ulcer will become infected. This increases the risk of further tissue damage and, in the face of frequent vascular disease, high-level amputation. Often all of this occurs with few, if any, symptoms until it is too late.

There is also good news. Studies have suggested that high-level amputations seem to decrease when interdisciplinary care is in place, regardless of the country.

Interdisciplinary teams consist of podiatric and vascular surgeons, the so-called Toe and Flow model. The concept is simple; these two specialists, can manage a great deal of the medical, surgical and biomechanical aspects of healing and aftercare.

When we add core physical therapy to this, then the threesome (what we in the field call Toe, Flow and Go) is really quite formidable. For example, our clinics at the University of Southern California and Rancho Los Amigos in Los Angeles have active participation from more than eight specialists ranging from plastic surgery to prosthetics/orthotics, to occupational therapy to nutrition to general practice to infectious disease to diabetology to nurse case management.

Truly, it takes a village to preserve a limb.

It has long been said in wound care that its not what one puts on a wound that heals it, but what one takes off. That maxim is absolutely true in the diabetic foot. Protection of the wound is key.

The gold standard for protecting the wound has been, believe it or not, to put the patient into a special cast. This device works so well because it protects the foot in a process known as offloading, or taking the burden off the foot. By its design, this cast is not easy to remove.

While this has been my personal favorite device to heal these foot wounds, patients dont like it and most doctors dont, either. In fact, fewer than 2% of centers in the country use this as their primary means of offloading. Reasons for this include fear of putting an open wound into a cast (even though the data largely refute this), the time required to apply and remove it and patients being miserable in a hot and heavy device.

Very recently, tech company offshoots have begun to partner with prosthetic/orthotic companies to create next-gen devices that can coax patients into wearing their protective device rather than forcing it upon them. They are using phone calls and a smartwatch.

After focusing on offloading pressure, the next question is what can be done to heal the wound.

Technologies ranging from fancy vacuums, to donated placental tissue, to repurposing blood cells into a dressing to topical oxygen systems have shown recent promise. Active research is being conducted with stem cell sheets consisting of specialized cells seeded on a clear sheet, spread-on skin, and gene therapy.

As challenging as healing the wound heals, the real challenge is whats next. Following healing, 40% of foot wounds will recur in one year, about two-thirds at three years, and nearly three out of four at five years.

At USC, along with colleagues in the National Health Service in the U.K., we have developed remission clinics designed to extend and promote an active life for this high-risk patient population.

This has also been combined with things like smart insoles, socks and home-based bathmats that can identify wounds before they occur. These technologies will likely initially be subscription-based but may expand beyond that.

Diabetic foot ulcers are common, complex and costly. Theyre sinister in that they come on quietly. Perhaps, though, it is now up to us to alert our own families, communities and leaders to this condition. It is, I believe, only by teaming up that we can stem the tide and preserve not only limbs, but extend lifespan, healthspan and hope.

[ Youre smart and curious about the world. So are The Conversations authors and editors. You can read us daily by subscribing to our newsletter. ]

Link:
Diabetic foot wounds kill millions, but high-tech solutions and teamwork are making a difference - The Conversation US

Toddler Bravely Cheats Death After He Survived Rare Cancer And Its Treatment – The Digital Weekly

Hailie and Treylin Hyman saw the bruising on their baby girls leg as a symbol that the active 1-year-old was getting to walk.

But as a blood test would following disclose and reveal, little Maci was suffering from an extremely unusual blood cancer that scared her life outwardly a risky treatment a practice nearly as serious as the disease.

At the start, it was very scary, Hailie Hyman told the reports.

Terrifying periods followed the diagnosis, punctuated by one crucial difficulty after another, starting the Boiling Springs couple to wonder if Maci would remain and survive or not.

The Hymans course started last February at Macis 1-year-old well-child checkup.

We had no clue anything was incorrect, her mom told. But they did a normal (blood test) and a few hours later, we attended a call telling her platelets were very low.

The Hymans was transferred to a hematologist who gained other abnormalities in Macis blood and listed a bone marrow biopsy to examine further.

During the treatment, the child endured an aneurysm in an artery and progressed into cardiac arrest. The medical team gave CPR for 20 minutes before she was steadied, her mom told.

Later, in the Emergency room, she underwent internal bleeding, too.

It was difficult, she told. There were many times that I would just pray and pray and pray.

Initially considering Maci had leukemia, doctors finally discovered she had myelodysplastic syndrome or MDS.

The situation occurs when abnormal cells in the bone marrow leave the patient weak and unable to make adequate blood.

In children, its more uncommon still. Most people are diagnosed in their 70s.

Maci had to produce regular blood transfusions, antibiotics, and other medicines to struggle the MDS, Bryant stated. But the only support for a remedy was a stem cell transplant.

The transplant is very risky.

Its also laden with possibly life-threatening difficulties, including graft vs. host disease, which happens when immune cells from the donor strike the patients body, Bryant told. Other difficulties incorporate permanent kidney damage and gastrointestinal problems.

There were so many moments during her initial months that it appeared like she would not survive, Bryant stated. So the fact that she is here is a miracle.

Macis family got an anonymous donor by the National Marrow Donor Program, participating many individuals to register in the process, Bryant told.

Maci was admitted to MUSC on June 5 and discharged on Oct. 14.

Go here to read the rest:
Toddler Bravely Cheats Death After He Survived Rare Cancer And Its Treatment - The Digital Weekly

‘My daughter’s death took me to the darkest place, but I’ve learned it’s possible to come back’ – Telegraph.co.uk

No one wants to talk about a dead child, Sheila Appiah says with unnerving calm as she stares into my eyes. Its any parents worst nightmare. I think it makes them frightened that it might happen to them, she explains, with a rueful smile.

People ask questions: How did she get the leukaemia? Did I not feed her the right food? Look, we had a healthy diet. We ate lots of fruits and vegetables. Imogin still got cancer.

We are drinking coffee in the cosy sitting room of the Croydon flat Appiah, now 47, moved into with her only child in 2004. In a telltale sign that this is a family home, the corner shelves display happy snaps of mother and daughter together: the bright eyes, high cheekbones and mischievous smiles mark a striking resemblance between the two.

More unusually, next to these are photos of Imogin with her doctors, Appiah with David Cameron, Imogin with Katie Price, and a handwritten note from the Duchess of York, addressed to Appiah, expressing sympathy at the loss of her daughter. The memories in this room are bittersweet: shortly after they settled into their first proper home, Imogin was diagnosed.

When we moved in, she was pretty feisty, running around, climbingup the sofa, wouldnt stay still, chatty, Appiah recalls with a laugh. Like any toddler, she would help with things; shed stand on a chair to wash plates. We were so, so close.

Go here to read the rest:
'My daughter's death took me to the darkest place, but I've learned it's possible to come back' - Telegraph.co.uk

Ausman family thankful for recoveries, support from family and community – Chippewa Herald

Paul Ausman and Raquel Hoepner-Ausman suffered traumatic brain injuries 16 days apart in April 2017. Two-and-a-half years later, both Paul and Raquel are on the comeback trail.

Paul Ausman was never shy about throwing a curveball during his days as a professional baseball pitcher.

But Ausman and his family have seen more curveballs in recent years than many families see in a lifetime.

After both Paul and his wife suffered significant brain ailments 16 days apart in April 2017, theyve continued battling and two-and-a-half years later they and their family are on the comeback trail.

While their road to recovery is far from over, they move into Thanksgiving improving every day with plenty to be thankful for.

Raquel and Paul's injuries came when their son Andrew (center) was a senior at McDonell. Andrew is now a junior at UW-Eau Claire.

Sixteen days

Raquel Hoepner-Ausman worked at Macys in Oakwood Mall for 26 years until the store closed in March 2017. A month later she collapsed after suffering a brain aneurysm in her familys home in Chippewa Falls and was taken to HSHS Sacred Heart Hospital in Eau Claire before being airlifted to Regions Hospital in St. Paul, Minnesota.

A little more than two weeks later, Paul was taken to the emergency room at HSHS St. Josephs Hospital in Chippewa Falls being before taken to Regions and diagnosed with having a brain tumor the size of a golf ball.

Both Paul and Raquel faced grueling recovery roads as their daughter Nikki lived in the Minneapolis with her family and a full-time job, and their younger son Andrew was finishing his senior year at McDonell.

A day after being admitted into Regions, Paul had a brain biopsy and was diagnosed with Lymphoma of the brain, and on May 4, 2017, had surgery for an enlarged lymph node.

Pauls vocal cord was accidentally nicked during the procedure and he lost his voice and could barely talk. The beginning of the same month, Raquel was transferred to a long-term care hospital in St. Paul and started to relearn to speak, eat and respond to commands.

She was later moved to a nursing home in Bloomer before needing brain surgery less than a year later to repair a blood vessel in her brain and had to start the process of relearning to eat, speak and respond to commands all over again.

Paul was approved for stem cell therapy and underwent his first attempt at a stem cell transplant on Sept. 28, 2017, in Rochester, Minn.

However, less than a month later, Paul was diagnosed with lymphoma cancer in both eyes, putting the stem cell transplant on hold while multiple surgeries were performed in both eyes to attempt to remove cancer cells. Follow-up chemotherapy injections into his eyes were performed until the start of the stem cell procedure, which he was able to restart in February 2018.

Paul was discharged from the stem cell transplant hospital on March 27, 2018, one day before Raquel had her brain surgery.

Raquel moved to the Rutledge home in Chippewa Falls in early June, across the street from the Ausman home, where she currently resides and rehabilitates.

Paul continued to receive chemotherapy shots in his eyes to keep the lymphoma in remission and recently has moved to a daily pill. Paul still makes monthly trips to Rochester as his body rebuilds its immune system.

B.A.T.

Paul graduated from Eau Claire Regis High School and was drafted in the 14th round of the 1973 Major League Baseball amateur draft by the Milwaukee Brewers. He played in the minor leagues for five seasons with the Brewers and Minnesota Twins, compiling a 2.93 earned run average across 147 games and 276 innings.

He reached as high as AAA with the Twins and nearly cracked the big league roster as the final cut during spring training.

The left hander shared the field with future Hall of Famers such as Robin Yount, Dave Winfield, Jack Morris, Rod Carew, Alan Trammel and Bert Blyleven before his career was finished after the 1977 season.

Paul would return to the area and earn his bachelor degree at the University of Wisconsin-Eau Claire before getting his masters from the University of Iowa.

He worked a number of jobs in the area, most recently as a store manager for the Mega Holiday station near the Family Fare grocery store downtown in Chippewa Falls.

When the Ausman family needed help, it came from a familiar face to the Chippewa Falls baseball community.

In the days and months after Paul and Raquel suffered their initial ailments, medical bills started piling up, as did the stress of figuring out how to take care of the bills. The family researched grants that could help them with their mounting medical costs, but nothing they found would shoulder the load.

Thats when Joe Vavra came into play.

The Chippewa Falls native and longtime MLB coach met Ausman after Vavra was drafted by the Los Angeles Dodgers in the eighth round of the 1982 draft.

We can't do it without you. Support local journalism with our BEST DEAL EVER!

Please call 877-782-0193 to upgrade your subscription.

Read the rest here:
Ausman family thankful for recoveries, support from family and community - Chippewa Herald

2nd Edition Africa Healthcare Extension Summit And Africa Women’s Health Summit Starts Today In Nairobi – Africa.com

The 2nd Edition Africa Healthcare Extension Summit and Africa Womens Health Summit launches today in Nairobi, Kenya, the leading event is organized by Verve Management UAE, and will be held over two days with participation of government officials from Ministries of Health across Africa, Regulatory Bodies, Healthcare Associations, stakeholders, Doctors, Obstetricians, Gynaecologists, Reproductive Medicine Specialists, Infertility Specialists and all other Medical Professionals.

AHES and AWHS is under the patronage of Ministries of Health Malawi, Zambia, Lesotho, Zimbabwe, Eswatini and being supported by Africa Healthcare Federation, Kenya Healthcare Federation and many more!

Key topics were discussed by industry professionals during the AHES sessions which included Role of Innovation in Augmenting healthcare, Healthcare Financing Systems in Africa, Alternative Forms of Healthcare Partnerships, Medical Devices Management Policy, Innovations & Changes in Cancer Therapy and Improving patient safety & quality in healthcare.

In healthcare, business as usual is not good enough, it will not achieve the goals we have set ourselves. So, we need innovation. But what is innovation exactly and how do we ensure that healthcare innovations have impact? I will be exploring these issues using my experience towards achieving a global impact in the treatment of diarrhoea in children. says, Simon Berry of ColaLife.

Very informative and networked conference that brings decision makers and projects together. An excellent opportunity for participants to understand key healthcare issues in the region while meeting key policy and decision makers. says, Salim Hasham of Health Services International.

AWHS topics includes Interventions in Obesity Management for Women, Current trends in the treatment of Polycrystic Ovary Syndrome, Understanding Endometriosis, Stem cells and other cell-based therapies. AWHS 2019 Eminent Speakers includes: Dr. Maureen Owiti (Kenyatta National Hospital), Dr. Navin Chander Raina (M.P. Shah Hospital), Dr. Elizabeth Gitau (Kenya Medical Association), Dr. Elizabeth Nakiyingi (Womens Hospital International and Fertility Centre) and many more!

AHES and AWHS 2019 is also grateful to this years sponsors: Varian Medical Systems, Vezeeta, Adwia, Boston Scientific, Renata Limited and Sukraa Software Solution.

Originally posted here:
2nd Edition Africa Healthcare Extension Summit And Africa Women's Health Summit Starts Today In Nairobi - Africa.com

How the Packers’ Za’Darius Smith brought joy and awareness to one woman’s cancer fight – The Athletic

Eileen Booker sat in her Southern California home last Sunday night, watching the Packers game like she does every week.

She grew up in Green Bay, and her sister still lives there. Her parents bought season tickets in 1957 and her father never missed a home game. She remembers sticking to frigid metal bleachers as a kid until the clock showed zeroes in the fourth quarter, win or lose, and always burning her lips with hot chocolate.

Still a die-hard fan today, Eileen was glued to her television for a prime-time game between the Packers and 49ers, even as her favorite team trailed, 10-0, early in the second quarter.

She had no idea her name was about to be plastered on TV screens across America.

After Packers outside linebacker ZaDarius Smith sacked 49ers quarterback Jimmy Garoppolo deep in 49ers territory, he immediately found the nearest camera and lifted his jersey, revealing a white undershirt that read, WE ...

See original here:
How the Packers' Za'Darius Smith brought joy and awareness to one woman's cancer fight - The Athletic

Thalassemia Treatment Market With Top Countries Data : Analysis and by Recent Trends and Regional Growth Overview Forecast 2026 – News Description

Transparency Market Research (TMR)has published a new report titled, Thalassemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026.According to the report, theglobal thalassemia treatment marketwas valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026. Increase in R&D investment by key players for developing new drugs for treating thalassemia and rise in demand for chelating therapy are anticipated to fuel the growth of the global market from 2018 to 2026. Asia Pacific and Middle East & Africa are expected to dominate the global market owing to increase in prevalence of thalassemia disorder and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients. The market in Asia Pacific is projected to expand at the fastest CAGR during the forecast period. Growth of the market in the region is attributed to large base of private clinics and hospitals, rise in number of thalassemia population requiring chelation therapy services after spleen surgery, and surge in adoption of blood transfusion among patients. The thalassemia treatment market in Latin America is likely to expand at a moderate growth rate during the forecast period.

Value Added Features in Thalassemia Treatments to Propel Global Market

The global thalassemia treatment market is projected to be driven by value added features offered by various thalassemia drug manufacturing companies in order to streamline the day to day work flow and increase revenue. The thalassemia treatment provides limited range of features and benefits ranging from patient pain heeling remedies to treatment procedures. For instance, very less number of people go for the much beneficial chelation therapy. These features help physicians and nurses to streamline the chelation therapy required for patients to maintain their daily workflow efficiently and effectively. Key players offering thalassemia treatment are coming up with value added features such as bone marrow transplantation, stem cell regeneration, gene editing methodologies, and effective modality features used for drug manufacturing along with creating a prominent candidate molecule for drugs. These features can reduce the overall operating cost and improve the overall effectiveness and efficiency of treatment practices. Companies are focusing on the development of combined drug therapy in their system to effectively integrate chelating therapy or other treatment procedure at an affordable cost. These value added features save time for physicians and help improve thalassemia patient survival performance.

Chelation Therapy to be Highly Lucrative Segment

Traditionally, blood transfusion based on type of thalassemia treatment was the most commonly used procedure among thalassemia patients. This treatment type was associated with availability of donor and cost of treatment procedure. Moreover, chelation therapy based on thalassemia treatment are priced on perpetual license model and are expensive. Chelation therapy treatment enables patients to practice intensive therapy to treat acute iron overload leading to 90% recovery among thalassemia patients. These chelation therapy based treatments address specific challenges faced during the treatment procedure. The chelation therapy treatment facilitates benefits such as pain relief, and increase in motion of blood flow among patients.

Request a PDF Brochure For the Thalassemia Treatment Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=44462

Asia Pacific Presents Significant Opportunities

North America and Europe accounted for major share of the global thalassemia treatment market in 2017 and are likely to gain market shares by 2026. High rate of immigration from tropical regions, increasing health care budgets by governments, and government initiatives to promote thalassemia treatment technique contributed to the leading share of these regions. Asia Pacific is projected to be the most attractive market for thalassemia treatment, with highest attractiveness index. The market in Asia Pacific is expected to expand at a high CAGR of 9% during the forecast period due to large number of thalassemia patients opting for chelation therapy in developing countries such as India and China. Well-established health care facilities, medical tourism for treatment of thalassemia, and high adoption of blood transfusion safety technique in countries such as Turkey and GCC Countries are likely to drive the market in Middle East & Africa. The market in Latin America is poised to expand at a moderate growth rate during the forecast period.

Trend of R&D among Leading Players to Increase Geographic Presence

The report also provides profiles of leading players operating in the global thalassemia treatment market. bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, and Shire plc (Takeda Pharmaceuticals) are the leading players operating in the global market. Companies operating in the thalassemia treatment market aim to increase geographic presence and research & development through strategic acquisitions and collaborations with leading players in respective domains and region. In December 2017, Shire plc committed to pay approximately US$ 1,409.9 Mn to contract vendors for administering and executing clinical trials. Other prominent players operating in the global thalassemia treatment include Incyte Corporation, Kiadis Pharma, Gamida Cell, Celgene Corporation, and Bellicum Pharmaceuticals.

Go here to see the original:
Thalassemia Treatment Market With Top Countries Data : Analysis and by Recent Trends and Regional Growth Overview Forecast 2026 - News Description

The ART of Having Children – Vision Insights and New Horizons

Im looking for a sperm donor, she said.

So begins Robert Klitzmans new book. If youre imagining that Klitzman is a provocative new writer of edgy cosmopolitan fiction, guess again. In Designing Babies: How Technology Is Changing the Ways We Create Children (2020), the medical doctor explores the many ways in which babies are created today. These ARTs (assisted reproductive technologies) may seem like fiction, but theyre not. Increasing numbers of hopeful parents are investing in ART procedures.

In vitro fertilization (or IVF, the bringing together of sperm and egg outside the body) is the core ART process. Since Louise Browns birth in 1978, IVF has added more than 8 million babies to both traditional and nontraditional families. But many millions more embryos and pregnancies have been unsuccessful. The grief, frustration and financial costs can be overwhelming; even the relationship between potential parents can be ruined by the unfulfilled dream of having an ART child. Meanwhile, leftover embryos are often kept in a frozen limbo awaiting destruction, gestational adoption, or parental retrieval for another round of treatment and possible birth.

So when a friend asked Klitzman, Do you want to be the father of my child? he had plenty to think about. You wouldnt have to do anything other than donate the sperm, she assured him. He writes that although the proposition was tempting, he worried, What if I disagreed with her about how to raise our child? He eventually told her no.

I have often wondered if I made the right decision. I will never know. But the choice helped me understand the predicaments that countless potential parents confront.

We now face crucial moral, social, cultural, psychological, and existential conundrums about how to employ these technologies, he remarks; whether to monitor or control them and, if so, how; and more broadly, where as a species we are or should be heading; and what responsibilities, if any, we have in these realms.

Echoing the advice of most scientists involved in this brave new world of designing babies, he writes, We need now to enhance discussion, awareness and understandings of these issues among patients, their families, clinicians in various fields, professional organizations, policymakers, and the public at large.

Klitzman is a professor of clinical psychiatry and director of the Masters of Bioethics Program at Columbia University. He also cofounded and codirected the Center for Bioethics and is a member of the Research Ethics Advisory Panel of the US Department of Defense and of the New York State Stem Cell Commission. His previous books include, among others, The Ethics Police? (2015) and Am I My Genes? (2012).

Vision contributor Dan Cloer spoke with Klitzman about what he discovered from writing Designing Babies. The conversation began with Chinese biophysics researcher He Jiankuis reasons for proceeding with germ-line editing of human embryos.

DC He Jiankuicreated a set of guidelines called Draft Ethical Principles for Therapeutic Assisted Reproductive Technologies to support his use of CRISPR for editing human embryos last year. How would you evaluate these principles?

RK They sound good, but we need more than nice words. With ethical principles, God is in the details, so to speak. The issue with any ethical principle is how it will be interpreted and applied. And what does one do when different ethical principles conflict? In general, Hes principles are fine, but they are not complete. Most specifically, what is missing for me is that he does not address questions of risk and external review.

Its not just that there may potentially be benefits to gene editing down the line, but what are the risks for someone today? Ideally, the CRISPR gene-editing tool might be used to intervene when no alternative treatment exists and the patient will otherwise die. In this case, there are good treatments for HIV and methods for avoiding transmission of HIV to a child. Gene editing was not necessary; the risks outweighed the benefits.

Researchers and policy makers around the world struggle to lead human germ-line editing into the future.

The other crucial element in international ethical guidelines is the need for a process of external review. Its not enough for scientists to say, Im going to cure people. I made this invention in my laboratory, and Im going to give it to everyone and save their lives! There must be an outside reviewer to say, Wait a second. What is it? What are the risks? What are you going to tell people about it?

We know that every scientist has conflicts of interest. They want their discovery, intervention or innovation to work. Unfortunately, there have been many cases where scientists, in their eagerness to show that their idea works, overlook risks and problems. For instance, one of Hes principles was Organizations developing genetic cures have a deep moral obligation to serve families of every background. We know now that he had plans to develop an offshore clinic to design babies for wealthy people around the world, who would come to wherever the clinic was located. That certainly shows a conflict of interest. Was he going to provide services for poor people too? Did he feel obliged by that statement to serve everyone?

DCIVF itself is very expensivemaybe $1520,000 for one treatment cycle. Thats a high bar for many right now, even before we start adding embryo gene sequencing and, at some point, gene editing. And there is no money-back guarantee.

RKThese technologies can help us and they can hurt us. They have the potential to make us better by eliminating some diseases, but also to make us more unequal by enhancing the children of people who can pay for it.

I suspect that CRISPR will eventually be introduced at fertility clinics in various countries. Someone will come along and offer somethingIQ, physical traits, other abilitiesand it will cost thousands of dollars.

For technologies that we are using right now, like Preimplantation Genetics Diagnosis (PGD, used to examine IVF embryos for abnormalities), we already face questions of equity and access. Its great that couples who may have inherited genes associated with breast cancer can have embryos examined and screened. But the procedure is expensive and often not covered by insurance. So wealthy people can afford to screen their embryos and maybe remove a disease like breast cancer from their family. Up to now, genetic diseases have been equal-opportunity killers. In the future, I think these conditions may increasingly become diseases of the poor. Obviously a lot of social questions arise when the wealthy can remove a mutation from their gene pool while others cannot.

DCYou say that your views concerning infertility changed while writing Designing Babies. What I saw astonished me, you write. These men and women shed light on the myriad, unforeseen facets and ramifications of these new technologies and dramatically altered my views. How so?

RKI started out in some ways wary of altering the genes of future generations. But I quickly realized that there are times when it might be helpful. PGD can be used to get rid of serious diseases. The key issue is to avoid bad uses and reduce the risks. Rather than saying that designing babies will be either good or bad, the question is when is it good, and when is it bad? It is not monolithic.

DCDo you see any ethical problem in creating IVF embryos that will be tested and rejected or passed on from the clinic to the lab to be used in research? What about surrogate gestation?

RKPersonally, nobut informed consent is important. We have hundreds of thousands of unused embryos in this country. Couples understandably dont want to throw them out, but sometimes they dont want to pay for storage either. But what is the moral status of an embryo? This is also an important question in the abortion and stem-cell debates. My opinion is that if a couple is trying to avoid passing on a gene associated with a serious disease, and some embryos have that gene, then its okay not to use these embryos. These are unfortunate choices that have to be made.

Similarly, I was quite wary of the idea of buying and selling eggs or sperm, or women renting their wombs [as gestational surrogates]. There are real concerns about exploitation of women and horror stories of children abandoned when the prospective parents changed their minds and no longer wanted the child after the surrogate gave birth. But as I looked into the issue through my interviews and learned about the women who were gestational surrogates, I found that many of them were not, in fact, being exploited. They knew what they were doing: Hey, I have two or three kids of my own and if I can make $90,000 just sitting around the house, that could help me pay for my kids college education.

DCSo you began to think differently because you were no longer just at your desk mulling it over academically?

RKExactly right. I wrote this book because the public debate is still focused on whether these technologies are good or bad. Whats missing are the voices of people who are personally involved, invested. Gloria Steinem tells the story of potential exploitation and impoverished women being forced to be surrogates against their will. At least in the US, the data do not support that. Certainly exploitation is bad, and we want to avoid it. But its not clear to me that it is happening. Doing research and finding out what the lived experiences are from the people involved really opened my eyes.

This speaks to the fact that many people dont yet know much about these technologies. Its true of gene editing but also of other forms of ART: buying and selling eggs and sperm, renting wombs. It affects lots of people but goes largely unexamined because there are taboos against talking about sex and reproduction. Men dont like to talk about impotence and low sperm count, feeling it means they are not macho. Women feel great shame about the fact that their eggs arent working or that theyve had to buy someone elses eggs, and that they are therefore not genetically related to their child. Theres secrecy and fear. Parents are afraid that their daughter wont love them as much if she finds out that her mom is not actually her genetic mother. But these secrets have costs. Kids may find these things out later and can become very upset and feel betrayed. Evidence suggests that children should be told from an early age that other people helped bring them into the world, or however a parent might want to communicate that.

I also came to realize how prevalent these issues are. In Denmark, for example, 7 percent of all births occur through some form of ART, and I believe that will soon be the number in the US. This is a big issue that we need to pay more attention to, on both the personal and the policy level. The CDC [Centers for Disease Control] collect some data, but theres more to do.

DCWe dont collect and apply data very well, you say. But there are things potential users of these technologies should knowdarker things that you learned as well.

RKWe do need data, but some issues stand out even now. We know that over 40 percent of twins born through IVF have medical problems. Yet fertility doctors, using IVF, commonly implant multiple embryos to increase the odds of a successful birth; its a selling point for the clinic. If Im an IVF doctor, I can say, Look at how many live births I have. Its good marketing, but not so good for the baby. I did not know this, and many IVF patients dont know it either. Thats why many European countries that provide national health-care coverage for IVF and for neonatal intensive care units have much stricter rules than we do in the US concerning the number of embryos doctors can transfer into the womb.

A lot of data could be readily gotten, but reporting is not mandatory, and many clinics dont want to provide their statistics. Clinics that dont report are actually increasing their business, so theres almost a reverse incentive. Changes in policy could address this problem, but unfortunately the lack of data is not accidental. Many clinics dont want to tell potential customers that there may be problems; they just want to say, Well bring a baby into your life. Some clinics dont want young women they recruit as egg donors to fully understand that the procedures might cause harms, such as Ovarian Hyperstimulation Syndrome, which can have serious symptoms. Collecting and publishing more data might reveal limitations and dangers.

I would say that more information is better for those who are considering using these procedures; but some IVF doctors dont want all the data out there, and they have had sway.

DCYouve called the ART industry in the United States a kind of Wild West in terms of the relative lack of regulation. Is there a business opportunity here to form some sort of watchdog group?

RKThe American Society for Reproductive Medicine (ASRM) and other physician organizations have done a good job of coming up with guidelines in many areas, but I think they can go further. For example, ASRM permits selecting the sex of a baby for family balancing. But what does that phrase really mean? A couple has one girl and now wants a boy? Or they have four girls and now want a boy? The organization needs to be more specific. The question of enforcement also arises. In terms of egg donation, we know that young womens eggs are biologically better. But should a doctor try to get 18- to 21-year-old women to sell their eggs? How risky is this for their own reproductive future? Guidelines say doctors should not recruit such young women, but clinics often do so anyway. Hence, even when there are guidelines, many clinics dont follow them and resist stronger guidelines. Today theres little if any consequence for not adhering to them.

In this Wild West, cowboys are often doing what they want without too much supervision. There are many wonderful IVF doctors; by no means am I saying they are all bad. But oversight and greater openness to potential limitations are important.

The danger of jumping in right now and attempting to design babies using CRISPR/gene editing is that we really dont know the full effects. Patients should be able to make fully informed decisions.

DCIn the real Wild West, people knew it was wild because they had a model of what civilization looked like. But we dont have a model for reference. Were building from scratch.

RKYes. Part of this is because of ever newer technologies. But just as with implanting multiple embryos, doctors widely usedand sometimes still usetechnologies that turned out to be more harmful and less beneficial than thought. A technique called ICSI [intracytoplasmic sperm injection] took one sperm from a man with a very low sperm count and injected it directly into an egg. Now ICSI is used for two thirds of all patients, without regard to the mans fertility. But the procedure turns out to double the risk of the child having intellectual disabilities. Unfortunately many potential parents dont realize this. It may help get you pregnant, but it can cause problems.

A major challenge of the Wild West is that doctors might be making a lot of money but may not always communicate the risks as well as they should, because they have a conflict of interest: profiting from what theyre doing.

DCWhere do your books Designing Babies and Am I My Genes? overlap?

RKAt one point scientists thought they would discover the cancer gene, the alcoholic gene, the schizophrenia gene. But lo and behold, were finding out that for most common diseases and traits, many genes are involved. Diseases can also be partly genetic, partly environmental. Theres a lot of nuance.

Listing the potential causes of a disease is like describing the possible reasons for a traffic jam: Did a car break down? Was there an accident? Is a bridge closed? Is it icy? Is it rush hour? Or some combination of those?

Several companies market direct-to-consumer genetic testing, pushing the idea that these services will give you important health information and help you get control of your health. Precision medicine can indeed potentially help many people. But our genetics are complicated. Am I My Genes? explored how genetic testing serves almost as a Rorschach, with people interpreting the information in varying ways.

The idea for Designing Babies grew from my work on Genes. When I interviewed people at risk for Huntingtons, I thought I would hear about issues of discrimination or insurance. But what I heard was concerns about their kidswhether to adopt or abort, or to test embryos. I heard a very disturbing observation: If I abort or dont choose an embryo because it has the same mutation that I have, I should have been aborted; am I saying that my life was not worth living? That question still haunts me. It made me want to investigate further the ethical, moral, social and psychological questions that assisted reproductive technologies present us.

The common element and challenge that comes from both books is that we still know relatively little about genes. Its been only 60 years or so since the discovery of the DNA helix and how hereditary information is encoded. The human genome was first sequenced less than 20 years ago. Much of what we have found is not what we expected.

DNA is becoming a second language of sorts because of its most attractive promise: customized, personalized medicine.

DCYou write about individual procreative liberty. Do you have any concern that in the future parents might be pressured to use ART to avoid creating an imperfect child? Could there be a time when national health care includes or compels IVF, and that parents who opt to have children with disease will be ostracized and lose access to social services because they willingly brought a baby into the world that would require more than its share of medical and support resources?

RKPast attempts to improve the genes of people led to horrific results. Nazi Germany sought to remove bad genes by killing people. Hitler got his ideas about eugenics from the United States and our unfortunate history of racism. In the 1920s, we had eugenics fairs and better-baby contests. So we need to be very careful about efforts to improve our genes.

Given our history, however, its hard to predict what the government will do. We know that at one point the government pushed sterilization of the so-called feebleminded. And the question of abortion is obviously very contentious.

The cost of IVF will be an important factor in shaping its possible future. We dont have enough money to provide basic health services to all citizens now. So even if IVF becomes more accessible and less expensive, which I think it will to a certain degree, I dont think it will ever be mandated. People just get pregnant naturally all the time, planned or unplanned. I dont think were going to get to the point where well just not support you unless you used IVF.

DCWhat is the most important question your book helps us explore?

RKWhat kind of society do we want in terms of our ability to design babieswhether choosing or discarding certain embryos; buying and selling human eggs, sperm, and embryos; or altering genes directly?

As with all technologies, ARTs can be used for good or for bad. How do we choose the good over the bad? Do we want to live in a world where people use all of these technologies with few limits? Undoubtedly everyone in America knows someone, whether they realize it or not, who has had infertility problems and has used these technologies. These patients journeys have often been lonely and isolating.

I think the book can help open up the conversation and assist us allas individuals, as friends and family members, and as a society as a wholein figuring out how best to use these technologies for our own good.

Go here to read the rest:
The ART of Having Children - Vision Insights and New Horizons